View Post

Research to remove exclusions on immunotherapy

In Clinical Trials by Barbara Jacoby

By: Michael Hardy From: mdanderson.org People used to ask Patrick Hwu, M.D., why he decided to devote his career to melanoma, a skin cancer with high mortality rates and limited treatment options. “They would come up to me and say, ‘How can you treat advanced melanoma? Isn’t that depressing?’ And actually, it was — my clinic of advanced melanoma patients …

View Post

Athenex Announces Completion of Target Enrollment in the Oraxol Phase III Study

In Clinical Trials by Barbara Jacoby

By: GlobeNewswire From: nasdaq.com Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that target enrollment of 360 patients in the Oraxol Phase III clinical trial in metastatic breast cancer has been achieved on schedule. Athenex also reaffirms that top line data from …

View Post

Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Carboplatin in Patients with Advanced or Metastatic Solid Tumors

In Clinical Trials by Barbara Jacoby

Source: Deciphera Pharmaceuticals, Inc. From: apnews.com Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it has initiated an open-label, multicenter, Phase 1b/2 study of rebastinib, the Company’s investigational small molecule switch control inhibitor of TIE2 kinase, in combination with carboplatin in patients with advanced or metastatic solid tumors. …

View Post

Researchers Suggest Current Methods for Reporting Toxicities in Cancer Clinical Trials are Falling Short

In Clinical Trials by Barbara Jacoby

Findings published in JNCCN examine the differences between patient- and clinician-reported outcomes; recommend a greater focus on the cumulative effect of multiple low-level toxicities. New research from Europe, published in the December 2018 issue of JNCCN—Journal of the National Comprehensive Cancer Network, finds that quality-of-life for people with cancer is reduced by an accumulation of low-level toxicities just as much …

View Post

CytRx Corporation Highlights Aldoxorubicin Included in New NantCell Inc. Triple Negative Breast Cancer Clinical Trial

In Clinical Trials by Barbara Jacoby

News provided by: CytRx Corporation From: prnewswire.com This New Trial Represents the Third NantCell Study Evaluating Aldoxorubicin Combined with Immunotherapy or Cell-Based Therapy CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks, LLC, has dosed the first patient in the Phase 1b portion of a …

View Post

Scientists develop system to rapidly and accurately detect tumor margins during breast cancer surgery

In Clinical Trials by Barbara Jacoby

From: medicalxpress.com Scientists from the RIKEN Cluster for Pioneering Research (CPR), Osaka University, and collaborators have developed a new rapid and inexpensive way to accurately detect the margins between cancer and non-cancerous tissue during breast surgery. Their system is noteworthy in that it can detect the morphology of the cells, differentiating between cells that are more or less dangerous. Today, …

View Post

Multiple Oncotype DX Study Presentations at the 2018 San Antonio Breast Cancer Symposium Reinforce Real-world Value of the Oncotype DX Breast Recurrence Score® Test in Patients Regardless of Age or Race

In Clinical Trials by Barbara Jacoby

News provided by: WCG/Genomic Health From: prnewswire.com Genomic Health, Inc. (NASDAQ: GHDX) today announced results from multiple Oncotype DX Breast Recurrence Score® (RS) presentations at the 2018 San Antonio Breast Cancer Symposium® (SABCS), reinforcing the value of the Oncotype DX® test in optimizing treatment and outcomes in patients with both node-negative and node-positive early-stage breast cancer. Among the data presented …

View Post

New clinical trials at Roswell Park build on virus research for innovative immunotherapy approach

In Clinical Trials by Barbara Jacoby

By: Katie Alexander From: www.wivb.com The Roswell Park Comprehensive Cancer Center is once again on the cutting-edge of research to find new cures, and Western New Yorkers could play a big role as clinical trials open for an innovative new approach to immunotherapy. Over the decades, there has been a lot of progress for certain types of cancers with immunotherapies, …

View Post

Combatting The Professional Patient Problem In Clinical Trials

In Clinical Trials by Barbara Jacoby

By: John Carlos Diaz, GeoSera Consulting From: clinicalleader.com Clinical research patients are compensated for their participation in clinical trials. The compensation is based on the burden the trial imposes on the patient and is vetted through an institutional review board, so patients are not overly influenced by financial gain to enroll. Unfortunately, in some therapeutic areas and types of clinical …